In this meta-analysis of 23 randomized CHF trials (>95% of patients had systolic dysfunction), pooled analysis showed beta blockers conferred a significant mortality benefit (risk ratio 0.76, CI 0.68-0.84). They did not find an association between mortality and beta blocker dose, but did find a linear association between mortality and heart rate (with an 18% relative risk reduction for every 5 fewer beats per minute). Beta blockers should be titrated by heart rate, not dose, to achieve mortality benefits in patients with systolic CHF (abstract).

This entry was posted on Monday, July 20th, 2009 at 8:54 pm and is filed under Cardiology. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.